-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, a series of industry policies represented by mass procurement of drugs, medical insurance control fees, reform of medical insurance payment methods, and consistency evaluation of generic drugs are profoundly transforming the Chinese pharmaceutical industry
.
Faced with the combined punches of the national giant palm, are the pharmaceutical companies beaten to death and eliminated sadly, or do they take advantage of their strength and take advantage of the momentum? This depends on the pharmaceutical companies' correct understanding of national policies, precise positioning of the company's strategy, rational use of corporate resources, continuous improvement of scientific research capabilities, and a keen response to market conditions
Medical insurance control fees and volume purchases are all right, and the growth rate of the pharmaceutical industry slows down
As China's population aging continues to intensify and the demand for national medicine continues to increase, the Chinese pharmaceutical market is thriving and has a promising future
.
However, at the same time, the pressure on the payment of medical insurance funds is increasing year by year.
In November 2018, the "National Organized Drug Centralized Procurement Pilot Program" was released, and mass procurement set off a bloody storm in the pharmaceutical market
.
In September 2019, the "4+7" centralized procurement was expanded.
The price reduction of medicines must be the main theme of the Chinese pharmaceutical market in recent years
.
After the first round of medical insurance catalogue negotiations in 2016, China's medical insurance catalogue has maintained a rhythm of updating once a year
.
According to statistics, the operating income of the pharmaceutical manufacturing industry will grow by 4.
Regardless of whether it wins the bid or not, no pharmaceutical company can stay outside of "purchasing with volume"
The volume purchases won the bid, and the pharmaceutical companies endured the drastic drop in drug prices
.
The quantity procurement failed to win the bid, and the big cake that was dug away caused the pharmaceutical companies to bleed heavily
Mass procurement is forcing pharmaceutical companies to fight from low-quality homogeneity, transforming and upgrading high-quality characteristic innovation
.
When volume purchases continue to gather resource advantages to leading enterprises, small and medium-sized enterprises must do a good job in their own planning and layout
It is worth noting that the vigorous advancement of the consistency evaluation of generic drugs and the expansion of the injection volume procurement scale have stimulated more and more competition in the injection market, and many pharmaceutical companies have begun to transform to the production of high-barrier high-end preparations
.
In the future, proprietary Chinese medicines and biological medicines will also be gradually included in the scope of volume procurement, continuing to create a huge wave in the pharmaceutical industry
In the era of mass procurement, improved innovative drugs may lead pharmaceutical companies to prominence
The implementation of the mass procurement policy announces that the era of high profits for domestic generic drugs is coming to an end
.
As the competition for generic drugs is becoming increasingly fierce, new and improved drugs between generic drugs and innovative drugs are ushering in new opportunities, and they are likely to emerge suddenly and become new hotspots in pharmaceutical research and development
In 2016, in order to encourage the creation of new drugs, improve the quality of drugs, and promote industrial upgrading, the National Food and Drug Administration issued the "Working Plan for the Reform of the Registration and Classification of Chemical Drugs" to reform the classification of chemical drugs, redefine "new drugs", and further divide them into 1 Class new drugs (innovative drugs) and Class 2 new drugs (improved new drugs)
.
Class 2 new drugs emphasize "superiority", which specifically refers to the optimization of their structure, dosage form, prescription technology, route of administration, indications, etc.
based on the known active ingredients, and has obvious clinical advantages, and both at home and abroad.
An improved new drug that is not on the market
.
The registration requirements for the new category 2 chemical drugs blocked the previously popular low-level modification of dosage forms and the route of administration into "new drugs"
.
Those drugs that ignore clinical value and "change for change" will be more difficult to gain a foothold
.
Enterprises must establish market-competitive R&D projects based on their own characteristics, base themselves on China, look at the world, and open the entrance to the internationalization of products to seek a broader market
.
Perhaps innovations such as "Global New" are too difficult and too big to be suitable for most companies in the industry, but improved innovation is a small step that everyone can try to take
.
In order to help the majority of pharmaceutical companies in the era of mass procurement, have a deep understanding of the historical evolution and future trends of the national medical cost control policy, and open up new ideas for the strategic layout of improved innovative drugs and generic drugs, the Wise Pharmaceutical Business School specially plans to launch a two-day " The road to medical cost control and drug development strategy breakthrough training meeting in the era of centralized procurement " , inviting senior experts in the field of policy research and drug research and development in the pharmaceutical industry, on May 14-15, through detailed data charts and vivid case introductions, profound The policy analysis and sharing of the R&D project strategy under the high-volume procurement allows enterprises to do more with less in the fierce market competition and highlight the encirclement
.
Everyone is welcome to sign up and discuss together! After registration, you can get the specific course outline of the training meeting
.